Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;
Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD.
Clin Chem. 2018 May;64(5):843-850. doi: 10.1373/clinchem.2017.285742. Epub 2018 Feb 7.
There is growing interest in fructosamine, glycated albumin, and 1,5-anhydroglucitol (1,5-AG) as alternative measures of hyperglycemia, particularly for use in settings where traditional measures (glucose and HbA1c) are problematic or where intermediate (2-4 weeks) glycemic control is of interest. However, reference intervals for these alternative biomarkers are not established.
We measured fructosamine, glycated albumin, and 1,5-AG in a community-based sample of US black and white adults who participated in the Atherosclerosis Risk in Communities (ARIC) Study. We calculated reference intervals, evaluated demographic differences, and derived cutoffs aligned with current diagnostic cutpoints for HbA1c and fasting glucose.
In a healthy reference population of 1799 individuals (mean age, 55 years; 51% women; 15% black), the 2.5 and 97.5 percentiles, respectively, were 194.8 and 258.0 μmol/L for fructosamine, 10.7% and 15.1% for glycated albumin, and 8.4 and 28.7 μg/mL for 1,5-AG. Distributions differed by race, sex, and body mass index. Equivalent concentrations of fructosamine and glycated albumin corresponding to an HbA1c of 6.5% (96.5 percentile) were 270.2 μmol/L and 15.6%, respectively. Equivalent concentrations of fructosamine and glycated albumin corresponding to a fasting glucose of 126 mg/dL (93.9 percentile) were 261.7 μmol/L and 15.0%, respectively.
The reference intervals for these biomarkers should inform their clinical use. Diagnostic cutpoint equivalents for fructosamine and glycated albumin could be useful to identify persons with hyperglycemia in settings where fasting glucose or HbA1c are not available or where the interpretation of these traditional measures is problematic.
果糖胺、糖化白蛋白和 1,5-脱水葡萄糖醇(1,5-AG)作为衡量高血糖的替代指标越来越受到关注,特别是在传统指标(血糖和 HbA1c)存在问题或需要评估中间(2-4 周)血糖控制情况的情况下。然而,这些替代生物标志物的参考区间尚未确定。
我们测量了参加动脉粥样硬化风险社区(ARIC)研究的美国黑人和白人成年人群体中的果糖胺、糖化白蛋白和 1,5-AG。我们计算了参考区间,评估了人口统计学差异,并根据 HbA1c 和空腹血糖的当前诊断切点得出了与切点一致的截断值。
在一个由 1799 名健康个体组成的参考人群中(平均年龄 55 岁,女性占 51%,黑人占 15%),果糖胺的第 2.5 和 97.5 百分位数分别为 194.8 和 258.0 μmol/L,糖化白蛋白的第 10.7%和 15.1%,1,5-AG 的第 8.4 和 28.7 μg/mL。分布因种族、性别和体重指数而异。相当于 HbA1c 为 6.5%(96.5 百分位数)的果糖胺和糖化白蛋白浓度分别为 270.2 μmol/L 和 15.6%。相当于空腹血糖为 126 mg/dL(93.9 百分位数)的果糖胺和糖化白蛋白浓度分别为 261.7 μmol/L 和 15.0%。
这些生物标志物的参考区间应指导其临床应用。果糖胺和糖化白蛋白的诊断切点等价物可能有助于在无法获得空腹血糖或 HbA1c 或这些传统指标的解释存在问题的情况下,识别患有高血糖的患者。